Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1981 Jun;11(6):597–603. doi: 10.1111/j.1365-2125.1981.tb01176.x

Sulphinpyrazone metabolism during long-term therapy.

A K Pedersen, P Jakobsen
PMCID: PMC1402191  PMID: 7272176

Abstract

1 The plasma concentrations of sulphinpyrazone and four of its metabolites are reported together with the amounts excreted in urine. Eight insulin-requiring diabetics were investigated, all treated with sulphinpyrazone 600-800 mg day-1 for 2.5 years or more. 2 Blood samples were drawn before the first morning dose and 2 h later. The mean plasma concentrations were (t=0 h-t=2 h): sulphinpyrazone 7.1-16.0 microgram ml-1; sulphone 1.7-4.8 microgram ml-1; p-OH-sulphide 0.67-0.89 microgram ml-1; p-OH-sulphinpyrazone 0.10-0.16 microgram ml-1. Statistically significant correlations were found between the plasma concentrations at t=0 of the sulphide and the p-OH-sulphide and that of sulphinpyrazone. 3 In urine, a very wide range in excretion of unconjugated compounds was observed. Sulphinpyrazone were excreted in amounts corresponding to 1-30% of the daily dose. The metabolites were generally excreted to amounts corresponding to less than 1% of the daily dose; however, up to 3% was found as the sulphone. 4 Increases of the concentration of all compounds in urine were found after treatment with beta-glucuronidase indicating 0-conjugation with glucuronic acid. 5 Since both the sulphide and the sulphone were found more active as inhibitors of platelet function in vitro than their parent compound, they may together constitute the major part of the platelet inhibitory drug activity in plasma during long-term therapy with sulphinpyrazone.

Full text

PDF
597

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarbakke J., Bakke O. M., Milde E. J., Davies D. S. Disposition and oxidative metabolism of phenylbutazone in man. Eur J Clin Pharmacol. 1977;11(5):359–366. doi: 10.1007/BF00566533. [DOI] [PubMed] [Google Scholar]
  2. Ali M., McDonald J. W. Effects of sulfinpyrazone on platelet prostaglandin synthesis and platelet release of serotonin. J Lab Clin Med. 1977 Apr;89(4):868–875. [PubMed] [Google Scholar]
  3. BRODIE B. B., YU T. F., BURNS J. J., CHENKIN T., PATON B. C., STEELE J. M., GUTMAN A. B. Observations on G-25671, a phenylbutazone analogue (4-phenylthioethyl)-1,2-diphenyl 3,5-pyrazolidinedione). Proc Soc Exp Biol Med. 1954 Aug-Sep;86(4):884–887. doi: 10.3181/00379727-86-21263. [DOI] [PubMed] [Google Scholar]
  4. BURNS J. J., YU T. F., RITTERBAND A., PEREL J. M., GUTMAN A. B., BRODIE B. B. A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671. J Pharmacol Exp Ther. 1957 Mar;119(3):418–426. [PubMed] [Google Scholar]
  5. Braunwald E. Treatment of the patient after myocardial infarction. The last decade and the next. N Engl J Med. 1980 Jan 31;302(5):290–293. doi: 10.1056/NEJM198001313020510. [DOI] [PubMed] [Google Scholar]
  6. Buchanan M. R., Rosenfeld J., Hirsh J. The prolonged effect of sulfinpyrazone on collagen-induced platelet aggregation in vivo. Thromb Res. 1978 Nov;13(5):883–892. doi: 10.1016/0049-3848(78)90193-7. [DOI] [PubMed] [Google Scholar]
  7. DAYTON P. G., SICAM L. E., LANDRAU M., BURNS J. J. Metabolism of sulfinpyrazone (Anturane) and other thio analogues of phenylbutazone in man. J Pharmacol Exp Ther. 1961 Jun;132:287–290. [PubMed] [Google Scholar]
  8. Dieterle W., Faigle J. W., Mory H., Richter W. J., Theobald W. Biotransformation and pharmacokinetics of sulfinpyrazone (Anturan) in man. Eur J Clin Pharmacol. 1975 Dec 19;9(2-3):135–145. doi: 10.1007/BF00614010. [DOI] [PubMed] [Google Scholar]
  9. Hucker H. B., Stauffer S. C., White S. D., Rhodes R. E., Arison B. H., Umbenhauer E. R., Bower R. J., McMahon F. G. Physiologic disposition and metabolic fate of a new anti-inflammatory agent, cis-5-fluro-2-methyl-1-(p-(methylsulfinyl)-benzylidenyl)-indene-3-acetic acid in the rat, dog, rhesus monkey, and man. Drug Metab Dispos. 1973 Nov-Dec;1(6):721–736. [PubMed] [Google Scholar]
  10. Jakobsen P., Pedersen A. K. Determination of sulfinpyrazone and two of its metabolites in human plasma and urine by gas chromatography and selective detection. J Chromatogr. 1979 Jul 21;163(3):259–269. doi: 10.1016/s0378-4347(00)81413-9. [DOI] [PubMed] [Google Scholar]
  11. Jakobsen P., Pedersen A. K. Two metabolites of sulphinpyrazone and their identification and determination by mass spectrometry. J Pharm Pharmacol. 1981 Feb;33(2):89–92. doi: 10.1111/j.2042-7158.1981.tb13717.x. [DOI] [PubMed] [Google Scholar]
  12. Lecaillon J. B., Souppart C., Schoeller J. P., Humbert G., Massias P. Sulfinpyrazone kinetics after intravenous and oral administration. Clin Pharmacol Ther. 1979 Nov;26(5):611–617. doi: 10.1002/cpt1979265611. [DOI] [PubMed] [Google Scholar]
  13. Pedersen A. K., Jakobsen P. Two new metabolites of sulfinpyrazone in the rabbit: a possible cause of the prolonged in vivo effect. Thromb Res. 1979;16(5-6):871–876. doi: 10.1016/0049-3848(79)90233-0. [DOI] [PubMed] [Google Scholar]
  14. Richter W. J., Alt K. O., Dieterle W., Faigle J. W., Kriemler H. P., Mory H., Winkler T. C-glucuronides, a novel type of drug metabolites. Helv Chim Acta. 1975 Dec 17;58(8):2512–2517. doi: 10.1002/hlca.19750580833. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES